

Arul M Chinnaiyan

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/1793766/arul-m-chinnaiyan-publications-by-year.pdf>

Version: 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

512
papers

86,873
citations

136
h-index

289
g-index

538
ext. papers

100,133
ext. citations

13.8
avg, IF

7.7
L-index

#	Paper	IF	Citations
512	Promoter Mutations in Keratinizing and Nonkeratinizing Squamous Metaplasia of the Urinary Tract.. <i>European Urology Open Science</i> , 2022 , 35, 74-78	0.9	0
511	Direct cellular reprogramming enables development of viral T antigen-driven Merkel cell carcinoma in mice.. <i>Journal of Clinical Investigation</i> , 2022 ,	15.9	1
510	Association of MyProstateScore (MPS) with prostate cancer grade in the radical prostatectomy specimen. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2022 , 40, 4.e1-4.e7	2.8	0
509	Biochemical characterization of the interaction between KRAS and Argonaute 2.. <i>Biochemistry and Biophysics Reports</i> , 2022 , 29, 101191	2.2	1
508	Defining cancer growth beyond the mitotic index.. <i>Nature Cell Biology</i> , 2022 , 24, 285-287	23.4	1
507	Metabolism drives macrophage heterogeneity in the tumor microenvironment.. <i>Cell Reports</i> , 2022 , 39, 110609	10.6	2
506	CRISPRs in the human genome are differentially expressed between malignant and normal adjacent to tumor tissue.. <i>Communications Biology</i> , 2022 , 5, 338	6.7	1
505	Leveraging artificial intelligence to predict ERG gene fusion status in prostate cancer.. <i>BMC Cancer</i> , 2022 , 22, 494	4.8	0
504	Targeting SWI/SNF ATPases in enhancer-addicted prostate cancer.. <i>Nature</i> , 2021 ,	50.4	10
503	G3BP1 inhibits Cul3 to amplify AR signaling and promote prostate cancer. <i>Nature Communications</i> , 2021 , 12, 6662	17.4	3
502	Epigenetically defined therapeutic targeting in H3.3G34R/V high-grade gliomas. <i>Science Translational Medicine</i> , 2021 , 13, eabf7860	17.5	2
501	Targeting integrated epigenetic and metabolic pathways in lethal childhood PFA ependymomas. <i>Science Translational Medicine</i> , 2021 , 13, eabc0497	17.5	3
500	HUGO Gene Nomenclature Committee (HGNC) recommendations for the designation of gene fusions. <i>Leukemia</i> , 2021 , 35, 3040-3043	10.7	10
499	Development of a Whole-urine, Multiplexed, Next-generation RNA-sequencing Assay for Early Detection of Aggressive Prostate Cancer. <i>European Urology Oncology</i> , 2021 ,	6.7	1
498	RNA-seq of human T cells after hematopoietic stem cell transplantation identifies as a regulator of T cell alloimmunity. <i>Science Translational Medicine</i> , 2021 , 13,	17.5	3
497	A Randomized Phase II Study of Androgen Deprivation Therapy with or without Palbociclib in RB-positive Metastatic Hormone-Sensitive Prostate Cancer. <i>Clinical Cancer Research</i> , 2021 , 27, 3017-3027	12.9	7
496	Cancer Cell Intrinsic and Immunologic Phenotypes Determine Clinical Outcomes in Basal-like Breast Cancer. <i>Clinical Cancer Research</i> , 2021 , 27, 3079-3093	12.9	5

495	Use of the MyProstateScore Test to Rule Out Clinically Significant Cancer: Validation of a Straightforward Clinical Testing Approach. <i>Journal of Urology</i> , 2021 , 205, 732-739	2.5	8
494	TRIM63 is a sensitive and specific biomarker for MiT family aberration-associated renal cell carcinoma. <i>Modern Pathology</i> , 2021 , 34, 1596-1607	9.8	4
493	Stanniocalcin 1 is a phagocytosis checkpoint driving tumor immune resistance. <i>Cancer Cell</i> , 2021 , 39, 480-493.e6	24.3	20
492	AGO2 promotes tumor progression in KRAS-driven mouse models of non-small cell lung cancer. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021 , 118,	11.5	3
491	CD38 in Advanced Prostate Cancers. <i>European Urology</i> , 2021 , 79, 736-746	10.2	0
490	Single-cell analyses of renal cell cancers reveal insights into tumor microenvironment, cell of origin, and therapy response. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021 , 118,	11.5	16
489	Constitutive Hedgehog/GLI2 signaling drives extracutaneous basaloid squamous cell carcinoma development and bone remodeling. <i>Carcinogenesis</i> , 2021 , 42, 1100-1109	4.6	
488	Association of Urinary MyProstateScore, Age, and Prostate Volume in a Longitudinal Cohort of Healthy Men: Long-term Findings from the Olmsted County Study. <i>European Urology Open Science</i> , 2021 , 29, 30-35	0.9	1
487	Germline variants discovered in lymphoma patients undergoing tumor profiling: a case series. <i>Familial Cancer</i> , 2021 , 20, 61-65	3	0
486	Immunotherapy for Conjunctival Squamous Cell Carcinoma with Orbital Extension. <i>Ophthalmology</i> , 2021 , 128, 801-804	7.3	4
485	Clinical application of next generation sequencing in lymphoma. <i>Leukemia and Lymphoma</i> , 2021 , 62, 868-873	10.3	1
484	TSLP-Driven Chromatin Remodeling and Trained Systemic Immunity after Neonatal Respiratory Viral Infection. <i>Journal of Immunology</i> , 2021 , 206, 1315-1328	5.3	4
483	Plasma cells are enriched in localized prostate cancer in Black men and are associated with improved outcomes. <i>Nature Communications</i> , 2021 , 12, 935	17.4	25
482	Assessment of Clinical Benefit of Integrative Genomic Profiling in Advanced Solid Tumors. <i>JAMA Oncology</i> , 2021 , 7, 525-533	13.4	19
481	A novel ATXN1-DUX4 fusion expands the spectrum of CIC-rearranged sarcoma of the CNS to include non-CIC alterations. <i>Acta Neuropathologica</i> , 2021 , 141, 619-622	14.3	2
480	De novo neuroendocrine transdifferentiation in primary prostate cancer-a phenotype associated with advanced clinico-pathologic features and aggressive outcome. <i>Medical Oncology</i> , 2021 , 38, 26	3.7	2
479	Proteogenomic insights into the biology and treatment of HPV-negative head and neck squamous cell carcinoma. <i>Cancer Cell</i> , 2021 , 39, 361-379.e16	24.3	50
478	Viral Status Predicts the Patterns of Genome Methylation and Decitabine Response in Merkel Cell Carcinoma. <i>Journal of Investigative Dermatology</i> , 2021 ,	4.3	1

477	A proteogenomic portrait of lung squamous cell carcinoma. <i>Cell</i> , 2021 , 184, 4348-4371.e40	56.2	15
476	Autophagy Inhibition by Targeting PIKfyve Potentiates Response to Immune Checkpoint Blockade in Prostate Cancer. <i>Nature Cancer</i> , 2021 , 2, 978-993	15.4	4
475	Is Universal Next-Generation Sequencing Testing of Patients With Advanced Cancer Ready for Prime Time?-Reply. <i>JAMA Oncology</i> , 2021 ,	13.4	9
474	Morphological cell profiling of SARS-CoV-2 infection identifies drug repurposing candidates for COVID-19. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021 , 118,	11.5	39
473	Comparative Molecular Analysis of Primary Central Nervous System Lymphomas and Matched Vitreoretinal Lymphomas by Vitreous Liquid Biopsy. <i>International Journal of Molecular Sciences</i> , 2021 , 22,	6.3	0
472	Liver metastasis restrains immunotherapy efficacy via macrophage-mediated T cell elimination. <i>Nature Medicine</i> , 2021 , 27, 152-164	50.5	117
471	Invasive squamous cell carcinomas and precursor lesions on UV-exposed epithelia demonstrate concordant genomic complexity in driver genes. <i>Modern Pathology</i> , 2020 , 33, 2280-2294	9.8	15
470	The role of the histone H3 variant CENPA in prostate cancer. <i>Journal of Biological Chemistry</i> , 2020 , 295, 8537-8549	5.4	23
469	An essential role for Argonaute 2 in EGFR-KRAS signaling in pancreatic cancer development. <i>Nature Communications</i> , 2020 , 11, 2817	17.4	9
468	Is the HERV-K HML-2 Xq21.33, an endogenous retrovirus mutated by gene conversion of chromosome X in a subset of African populations, associated with human breast cancer?. <i>Infectious Agents and Cancer</i> , 2020 , 15, 19	3.5	3
467	Mutations predictive of hyperactive Ras signaling correlate with inferior survival across high-risk pediatric acute leukemia. <i>Translational Pediatrics</i> , 2020 , 9, 43-50	4.2	3
466	Differential modulation of the androgen receptor for prostate cancer therapy depends on the DNA response element. <i>Nucleic Acids Research</i> , 2020 , 48, 4741-4755	20.1	7
465	Diffuse intrinsic pontine glioma-like tumor with EZHIP expression and molecular features of PFA ependymoma. <i>Acta Neuropathologica Communications</i> , 2020 , 8, 37	7.3	8
464	Wnt Signaling Drives Prostate Cancer Bone Metastatic Tropism and Invasion. <i>Translational Oncology</i> , 2020 , 13, 100747	4.9	18
463	Proteogenomic Characterization Reveals Therapeutic Vulnerabilities in Lung Adenocarcinoma. <i>Cell</i> , 2020 , 182, 200-225.e35	56.2	139
462	The MD Anderson Prostate Cancer Patient-derived Xenograft Series (MDA PCa PDX) Captures the Molecular Landscape of Prostate Cancer and Facilitates Marker-driven Therapy Development. <i>Clinical Cancer Research</i> , 2020 , 26, 4933-4946	12.9	19
461	Polypoidal giant cancer cells in metastatic castration-resistant prostate cancer: observations from the Michigan Legacy Tissue Program. <i>Medical Oncology</i> , 2020 , 37, 16	3.7	5
460	TAMI-42. H3K27M MUTANT GLIOMAS HIJACK A CONSERVED AND CRITICAL METABOLIC PATHWAY USED BY IDH1 MUTANT GLIOMAS TO MAINTAIN THEIR PREFERRED EPIGENETIC STATE. <i>Neuro-Oncology</i> , 2020 , 22, ii222-ii222	1	

459	Role of Aneuploidy in Transcriptional Regulation and Clinical Prognosis in Relapsed and/or Refractory Multiple Myeloma (RRMM). <i>Blood</i> , 2020 , 136, 45-46	2.2	0
458	CTNI-17. CLINICAL EFFICACY AND PREDICTIVE BIOMARKERS OF ONC201 IN H3 K27M-MUTANT DIFFUSE MIDLINE GLIOMA. <i>Neuro-Oncology</i> , 2020 , 22, ii45-ii46	1	
457	TTK inhibition radiosensitizes basal-like breast cancer through impaired homologous recombination. <i>Journal of Clinical Investigation</i> , 2020 , 130, 958-973	15.9	28
456	Everolimus improves the efficacy of dasatinib in PDGFR β -driven glioma. <i>Journal of Clinical Investigation</i> , 2020 , 130, 5313-5325	15.9	13
455	Epigenetic driver mutations in ARID1A shape cancer immune phenotype and immunotherapy. <i>Journal of Clinical Investigation</i> , 2020 , 130, 2712-2726	15.9	45
454	Double-Negative Prostate Cancer Masquerading as a Squamous Cancer of Unknown Primary: A Clinicopathologic and Genomic Sequencing-Based Case Study. <i>JCO Precision Oncology</i> , 2020 , 4,	3.6	2
453	The comprehensive methylation landscape of metastatic castration-resistant prostate cancer (mCRPC) identifies new phenotypic subtypes: Results from the West Coast Prostate Cancer Dream Team (WCDT).. <i>Journal of Clinical Oncology</i> , 2020 , 38, 5507-5507	2.2	
452	DIPG-59. UPREGULATION OF PRENATAL PONTINE ID1 SIGNALING IN DIPG. <i>Neuro-Oncology</i> , 2020 , 22, iii298-iii299	1	78
451	Case Study: Systematic Detection and Prioritization of Gene Fusions in Cancer by RNA-Seq: A DIY Toolkit. <i>Methods in Molecular Biology</i> , 2020 , 2079, 69-79	1.4	3
450	Androgen receptor degraders overcome common resistance mechanisms developed during prostate cancer treatment. <i>Neoplasia</i> , 2020 , 22, 111-119	6.4	58
449	PAX8 expression and TERT promoter mutations in the nested variant of urothelial carcinoma: a clinicopathologic study with immunohistochemical and molecular correlates. <i>Modern Pathology</i> , 2020 , 33, 1165-1171	9.8	10
448	TERT- beyond the territory: Usage of PCR-based TERT promoter assay in defining urothelial carcinoma in a case of long-standing prostatic adenocarcinoma. <i>Pathology Research and Practice</i> , 2020 , 216, 152663	3.4	1
447	Correlation between cribriform/intraductal prostatic adenocarcinoma and percent Gleason pattern 4 to a 22-gene genomic classifier. <i>Prostate</i> , 2020 , 80, 146-152	4.2	11
446	Clinicopathological characterisation of renal cell carcinoma in young adults: a contemporary update and review of literature. <i>Histopathology</i> , 2020 , 76, 875-887	7.3	5
445	Multivalent Proteins Rapidly and Reversibly Phase-Separate upon Osmotic Cell Volume Change. <i>Molecular Cell</i> , 2020 , 79, 978-990.e5	17.6	20
444	The Potential of Circular RNAs as Cancer Biomarkers. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2020 , 29, 2541-2555	4	7
443	Clinical Sequencing of High-Grade Undifferentiated Sarcomas: A Case Series and Report of an Aggressive Primary Cardiac Tumor With Multiple Oncogenic Drivers. <i>JCO Precision Oncology</i> , 2020 , 4,	3.6	
442	Impact of the MyProstateScore (MPS) Test on the Clinical Decision to Undergo Prostate Biopsy: Results From a Contemporary Academic Practice. <i>Urology</i> , 2020 , 145, 204-210	1.6	2

441	The DNA methylation landscape of advanced prostate cancer. <i>Nature Genetics</i> , 2020 , 52, 778-789	36.3	71
440	Accelerating precision medicine in metastatic prostate cancer. <i>Nature Cancer</i> , 2020 , 1, 1041-1053	15.4	18
439	Expression of the Androgen Receptor Governs Radiation Resistance in a Subset of Glioblastomas Vulnerable to Antiandrogen Therapy. <i>Molecular Cancer Therapeutics</i> , 2020 , 19, 2163-2174	6.1	6
438	Integrated Metabolic and Epigenomic Reprograming by H3K27M Mutations in Diffuse Intrinsic Pontine Gliomas. <i>Cancer Cell</i> , 2020 , 38, 334-349.e9	24.3	30
437	Cancer SLC43A2 alters T cell methionine metabolism and histone methylation. <i>Nature</i> , 2020 , 585, 277-283	20.4	98
436	Clinical Outcomes in Cyclin-dependent Kinase 12 Mutant Advanced Prostate Cancer. <i>European Urology</i> , 2020 , 77, 333-341	10.2	39
435	Next-generation RNA Sequencing-based Biomarker Characterization of Chromophobe Renal Cell Carcinoma and Related Oncocytic Neoplasms. <i>European Urology</i> , 2020 , 78, 63-74	10.2	26
434	-Mutated Prostate Cancer: Clinical Outcomes With Standard Therapies and Immune Checkpoint Blockade. <i>JCO Precision Oncology</i> , 2020 , 4, 382-392	3.6	26
433	Targeting transcriptional regulation of SARS-CoV-2 entry factors and. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020 ,	11.5	74
432	Plasmacytoid urothelial carcinoma: a rapid autopsy case report with unique clinicopathologic and genomic profile. <i>Diagnostic Pathology</i> , 2019 , 14, 113	3	2
431	Radiotherapy and Immunotherapy Promote Tumoral Lipid Oxidation and Ferroptosis via Synergistic Repression of SLC7A11. <i>Cancer Discovery</i> , 2019 , 9, 1673-1685	24.4	252
430	A clonal expression biomarker associates with lung cancer mortality. <i>Nature Medicine</i> , 2019 , 25, 1540-1548	18.5	34
429	Distinct structural classes of activating FOXA1 alterations in advanced prostate cancer. <i>Nature</i> , 2019 , 571, 413-418	50.4	96
428	Genomic correlates of clinical outcome in advanced prostate cancer. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2019 , 116, 11428-11436	11.5	383
427	CD8 T cells regulate tumour ferroptosis during cancer immunotherapy. <i>Nature</i> , 2019 , 569, 270-274	50.4	632
426	Pediatric craniopharyngioma in association with familial adenomatous polyposis. <i>Familial Cancer</i> , 2019 , 18, 327-330	3	4
425	Functional and Mechanistic Interrogation of BET Bromodomain Degradors for the Treatment of Metastatic Castration-resistant Prostate Cancer. <i>Clinical Cancer Research</i> , 2019 , 25, 4038-4048	12.9	16
424	Dynamic Recruitment of Single RNAs to Processing Bodies Depends on RNA Functionality. <i>Molecular Cell</i> , 2019 , 74, 521-533.e6	17.6	58

423	Activation of MAPK Signaling by CXCR7 Leads to Enzalutamide Resistance in Prostate Cancer. <i>Cancer Research</i> , 2019 , 79, 2580-2592	10.1	42
422	Characterizing the Therapeutic Potential of a Potent BET Degradator in Merkel Cell Carcinoma. <i>Neoplasia</i> , 2019 , 21, 322-330	6.4	5
421	The Landscape of Circular RNA in Cancer. <i>Cell</i> , 2019 , 176, 869-881.e13	56.2	672
420	Polycomb group proteins EZH2 and EED directly regulate androgen receptor in advanced prostate cancer. <i>International Journal of Cancer</i> , 2019 , 145, 415-426	7.5	32
419	Clinical and morphologic review of 60 hereditary renal tumors from 30 hereditary renal cell carcinoma syndrome patients: lessons from a contemporary single institution series. <i>Medical Oncology</i> , 2019 , 36, 74	3.7	9
418	DNA-Dependent Protein Kinase Drives Prostate Cancer Progression through Transcriptional Regulation of the Wnt Signaling Pathway. <i>Clinical Cancer Research</i> , 2019 , 25, 5608-5622	12.9	10
417	Integrative Exome and Transcriptome Analysis of Conjunctival Melanoma and Its Potential Application for Personalized Therapy. <i>JAMA Ophthalmology</i> , 2019 , 137, 1444-1448	3.9	11
416	Integrated Proteogenomic Characterization of Clear Cell Renal Cell Carcinoma. <i>Cell</i> , 2019 , 179, 964-983.e31	58.1	173
415	Aneuploidy Is Associated with Inferior Survival in Relapsed Refractory Multiple Myeloma Patients. <i>Blood</i> , 2019 , 134, 4360-4360	2.2	1
414	SUN-003 Targeting Androgen Receptor-CXCR7-MARK Signaling Axis in CRPC. <i>Journal of the Endocrine Society</i> , 2019 , 3,	0.4	78
413	Integrated Genomic-Transcriptomic Study Highlights Accumulation of Genetic Variants and Activation of Inflammatory Pathways. <i>Blood</i> , 2019 , 134, 4212-4212	2.2	
412	Metastatic castration resistant prostate cancer with squamous cell, small cell, and sarcomatoid elements-a clinicopathologic and genomic sequencing-based discussion. <i>Medical Oncology</i> , 2019 , 36, 27	3.7	5
411	Transcriptomic Heterogeneity of Androgen Receptor Activity Defines a low AR-Active Subclass in Treatment Naïve Primary Prostate Cancer. <i>Clinical Cancer Research</i> , 2019 , 25, 6721-6730	12.9	35
410	The Role of Non-coding RNAs in Oncology. <i>Cell</i> , 2019 , 179, 1033-1055	56.2	413
409	The utility of upper urinary tract urine cytology before and after application of the Paris system. <i>Diagnostic Cytopathology</i> , 2019 , 47, 421-427	1.4	10
408	Next-generation sequencing in precision oncology: Patient understanding and expectations. <i>Cancer Medicine</i> , 2019 , 8, 227-237	4.8	20
407	Genomic Analysis of Three Metastatic Prostate Cancer Patients with Exceptional Responses to Carboplatin Indicating Different Types of DNA Repair Deficiency. <i>European Urology</i> , 2019 , 75, 184-192	10.2	49
406	Clinical utility and concordance of upper urinary tract cytology and biopsy in predicting clinicopathological features of upper urinary tract urothelial carcinoma. <i>Human Pathology</i> , 2019 , 86, 76-84	3.7	7

405	MechRNA: prediction of lncRNA mechanisms from RNA-RNA and RNA-protein interactions. <i>Bioinformatics</i> , 2018 , 34, 3101-3110	7.2	35
404	Multigene Profiling of CTCs in mCRPC Identifies a Clinically Relevant Prognostic Signature. <i>Molecular Cancer Research</i> , 2018 , 16, 643-654	6.6	24
403	Detailed pathologic analysis on the co-occurrence of non-seminomatous germ cell tumor subtypes in matched orchiectomy and retroperitoneal lymph node dissections. <i>Medical Oncology</i> , 2018 , 35, 21	3.7	3
402	Cancer transcriptome profiling at the juncture of clinical translation. <i>Nature Reviews Genetics</i> , 2018 , 19, 93-109	30.1	128
401	The CARMA3-Bcl10-MALT1 Signalosome Drives NF κ B Activation and Promotes Aggressiveness in Angiotensin II Receptor-Positive Breast Cancer. <i>Cancer Research</i> , 2018 , 78, 1225-1240	10.1	48
400	Precision oncology in the age of integrative genomics. <i>Nature Biotechnology</i> , 2018 , 36, 46-60	44.5	65
399	Circumscribed/non-diffuse histology confers a better prognosis in H3K27M-mutant gliomas. <i>Acta Neuropathologica</i> , 2018 , 135, 299-301	14.3	34
398	BRAF activating mutations involving the B-IT loop in V600E-negative anaplastic pleomorphic xanthoastrocytoma. <i>Acta Neuropathologica Communications</i> , 2018 , 6, 24	7.3	9
397	The long tail of oncogenic drivers in prostate cancer. <i>Nature Genetics</i> , 2018 , 50, 645-651	36.3	380
396	Targeting Bromodomain and Extra-Terminal (BET) Family Proteins in Castration-Resistant Prostate Cancer (CRPC). <i>Clinical Cancer Research</i> , 2018 , 24, 3149-3162	12.9	77
395	Comprehensive Evaluation of Programmed Death-Ligand 1 Expression in Primary and Metastatic Prostate Cancer. <i>American Journal of Pathology</i> , 2018 , 188, 1478-1485	5.8	79
394	The utility of SDHB and FH immunohistochemistry in patients evaluated for hereditary paraganglioma-pheochromocytoma syndromes. <i>Human Pathology</i> , 2018 , 71, 47-54	3.7	30
393	miR-34a Regulates Expression of the Stathmin-1 Oncoprotein and Prostate Cancer Progression. <i>Molecular Cancer Research</i> , 2018 , 16, 1125-1137	6.6	31
392	Detection of 6 TFEB-amplified renal cell carcinomas and 25 renal cell carcinomas with MITF translocations: systematic morphologic analysis of 85 cases evaluated by clinical TFE3 and TFEB FISH assays. <i>Modern Pathology</i> , 2018 , 31, 179-197	9.8	46
391	Physician Experiences and Understanding of Genomic Sequencing in Oncology. <i>Journal of Genetic Counseling</i> , 2018 , 27, 187-196	2.5	13
390	Frequent PD-L1 Protein Expression and Molecular Correlates in Urinary Bladder Squamous Cell Carcinoma. <i>European Urology</i> , 2018 , 74, 529-531	10.2	11
389	Competing for enhancers: PVT1 fine-tunes MYC expression. <i>Cell Research</i> , 2018 , 28, 785-786	24.7	11
388	Genomic Hallmarks and Structural Variation in Metastatic Prostate Cancer. <i>Cell</i> , 2018 , 174, 758-769.e9	56.2	234

387	Medulloblastoma therapy generates risk of a poorly-prognostic H3 wild-type subgroup of diffuse intrinsic pontine glioma: a report from the International DIPG Registry. <i>Acta Neuropathologica Communications</i> , 2018 , 6, 67	7.3	7
386	Epigenetic Reprogramming with Antisense Oligonucleotides Enhances the Effectiveness of Androgen Receptor Inhibition in Castration-Resistant Prostate Cancer. <i>Cancer Research</i> , 2018 , 78, 5731-5740	19.1	29
385	Inactivation of CDK12 Delineates a Distinct Immunogenic Class of Advanced Prostate Cancer. <i>Cell</i> , 2018 , 173, 1770-1782.e14	56.2	256
384	A precision oncology approach to the pharmacological targeting of mechanistic dependencies in neuroendocrine tumors. <i>Nature Genetics</i> , 2018 , 50, 979-989	36.3	90
383	Transcriptomic heterogeneity in multifocal prostate cancer. <i>JCI Insight</i> , 2018 , 3,	9.9	41
382	Host expression of PD-L1 determines efficacy of PD-L1 pathway blockade-mediated tumor regression. <i>Journal of Clinical Investigation</i> , 2018 , 128, 805-815	15.9	252
381	Integrative Next Generation Sequencing of Myeloproliferative Neoplasms and Correlation of Genetic Variations to Disease Severity. <i>Blood</i> , 2018 , 132, 4324-4324	2.2	1
380	Dynamic changes during the treatment of pancreatic cancer. <i>Oncotarget</i> , 2018 , 9, 14764-14790	3.3	11
379	Comprehensive Mutation and Copy Number Profiling in Archived Circulating Breast Cancer Tumor Cells Documents Heterogeneous Resistance Mechanisms. <i>Cancer Research</i> , 2018 , 78, 1110-1122	10.1	60
378	Development of the CNS TAP tool for the selection of precision medicine therapies in neuro-oncology. <i>Journal of Neuro-Oncology</i> , 2018 , 137, 155-169	4.8	7
377	Targeting the MYCN-PARP-DNA Damage Response Pathway in Neuroendocrine Prostate Cancer. <i>Clinical Cancer Research</i> , 2018 , 24, 696-707	12.9	51
376	Clinical validation of the Tempus xO assay. <i>Oncotarget</i> , 2018 , 9, 25826-25832	3.3	20
375	VSTM2A Overexpression Is a Sensitive and Specific Biomarker for Mucinous Tubular and Spindle Cell Carcinoma (MTSCC) of the Kidney. <i>American Journal of Surgical Pathology</i> , 2018 , 42, 1571-1584	6.7	24
374	Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. <i>Journal of Clinical Oncology</i> , 2018 , 36, 991-999	2.2	117
373	Immunogenomic analyses associate immunological alterations with mismatch repair defects in prostate cancer. <i>Journal of Clinical Investigation</i> , 2018 , 128, 4441-4453	15.9	84
372	Clinically Integrated Sequencing Alters Therapy in Children and Young Adults With High-Risk Glial Brain Tumors. <i>JCO Precision Oncology</i> , 2018 , 2,	3.6	7
371	Association of ERG/PTEN status with biochemical recurrence after radical prostatectomy for clinically localized prostate cancer. <i>Medical Oncology</i> , 2018 , 35, 152	3.7	11
370	MiPanda: A Resource for Analyzing and Visualizing Next-Generation Sequencing Transcriptomics Data. <i>Neoplasia</i> , 2018 , 20, 1144-1149	6.4	10

369	Analysis of the androgen receptor-regulated lncRNA landscape identifies a role for ARLNC1 in prostate cancer progression. <i>Nature Genetics</i> , 2018 , 50, 814-824	36.3	124
368	Genetic diversity of NDUFB1-dependent mitochondrial complex I deficiency. <i>European Journal of Human Genetics</i> , 2018 , 26, 1582-1587	5.3	8
367	Somatic Bi-allelic Loss of TSC Genes in Eosinophilic Solid and Cystic Renal Cell Carcinoma. <i>European Urology</i> , 2018 , 74, 483-486	10.2	41
366	miR-34a directly targets tRNA precursors and affects cellular proliferation, cell cycle, and apoptosis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018 , 115, 7392-7397	11.5	33
365	Programmed Death-ligand 1 Expression in Upper Tract Urothelial Carcinoma. <i>European Urology Focus</i> , 2017 , 3, 502-509	5.1	18
364	Associations of Luminal and Basal Subtyping of Prostate Cancer With Prognosis and Response to Androgen Deprivation Therapy. <i>JAMA Oncology</i> , 2017 , 3, 1663-1672	13.4	138
363	Immunohistochemical Characterization of Fumarate Hydratase (FH) and Succinate Dehydrogenase (SDH) in Cutaneous Leiomyomas for Detection of Familial Cancer Syndromes. <i>American Journal of Surgical Pathology</i> , 2017 , 41, 801-809	6.7	20
362	Circulating Cell-Free DNA to Guide Prostate Cancer Treatment with PARP Inhibition. <i>Cancer Discovery</i> , 2017 , 7, 1006-1017	24.4	232
361	Age and Gender Associations of Virus Positivity in Merkel Cell Carcinoma Characterized Using a Novel RNA Hybridization Assay. <i>Clinical Cancer Research</i> , 2017 , 23, 5622-5630	12.9	22
360	Development of Peptidomimetic Inhibitors of the ERG Gene Fusion Product in Prostate Cancer. <i>Cancer Cell</i> , 2017 , 31, 532-548.e7	24.3	57
359	Clinical characteristics and whole exome/transcriptome sequencing of coexisting chronic myeloid leukemia and myelofibrosis. <i>American Journal of Hematology</i> , 2017 , 92, 555-561	7.1	7
358	Preclinical Evaluation of C-Sarcosine as a Substrate of Proton-Coupled Amino Acid Transporters and First Human Application in Prostate Cancer. <i>Journal of Nuclear Medicine</i> , 2017 , 58, 1216-1223	8.9	8
357	SPOP Mutation Drives Prostate Tumorigenesis In Vivo through Coordinate Regulation of PI3K/mTOR and AR Signaling. <i>Cancer Cell</i> , 2017 , 31, 436-451	24.3	116
356	Rare Presentation of Metastatic Cystic Trophoblastic Tumor in a Patient Without Prior Chemotherapy. <i>Urology Case Reports</i> , 2017 , 13, 154-157	0.5	3
355	Gene Copy Number Estimation from Targeted Next-Generation Sequencing of Prostate Cancer Biopsies: Analytic Validation and Clinical Qualification. <i>Clinical Cancer Research</i> , 2017 , 23, 6070-6077	12.9	22
354	Integrative clinical genomics of metastatic cancer. <i>Nature</i> , 2017 , 548, 297-303	50.4	440
353	Blood-brain barrier-adapted precision medicine therapy for pediatric brain tumors. <i>Translational Research</i> , 2017 , 188, 27.e1-27.e14	11	10
352	Comprehensive Molecular Profiling of Olfactory Neuroblastoma Identifies Potentially Targetable Amplifications. <i>Molecular Cancer Research</i> , 2017 , 15, 1551-1557	6.6	25

351	Oncogenic Role of THOR, a Conserved Cancer/Testis Long Non-coding RNA. <i>Cell</i> , 2017 , 171, 1559-1572. e302	30.2	153
350	Rapid molecular assays to study human centromere genomics. <i>Genome Research</i> , 2017 , 27, 2040-2049	9.7	16
349	Precision medicine in pediatric oncology: Lessons learned and next steps. <i>Pediatric Blood and Cancer</i> , 2017 , 64, e26288	3	51
348	Expression and Role of PAICS, a De Novo Purine Biosynthetic Gene in Prostate Cancer. <i>Prostate</i> , 2017 , 77, 10-21	4.2	27
347	The Emergence of Precision Urologic Oncology: A Collaborative Review on Biomarker-driven Therapeutics. <i>European Urology</i> , 2017 , 71, 237-246	10.2	41
346	Development of a RNA-Seq Based Prognostic Signature in Lung Adenocarcinoma. <i>Journal of the National Cancer Institute</i> , 2017 , 109,	9.7	110
345	Genome-Wide STAT3 Binding Analysis after Histone Deacetylase Inhibition Reveals Novel Target Genes in Dendritic Cells. <i>Journal of Innate Immunity</i> , 2017 , 9, 126-144	6.9	8
344	TACO produces robust multisample transcriptome assemblies from RNA-seq. <i>Nature Methods</i> , 2017 , 14, 68-70	21.6	72
343	Rapid, ultra low coverage copy number profiling of cell-free DNA as a precision oncology screening strategy. <i>Oncotarget</i> , 2017 , 8, 89848-89866	3.3	36
342	Next generation sequencing of extraskeletal myxoid chondrosarcoma. <i>Oncotarget</i> , 2017 , 8, 21770-21777	3.3	15
341	Two-pass alignment improves novel splice junction quantification. <i>Bioinformatics</i> , 2016 , 32, 43-9	7.2	21
340	Lowered H3K27me3 and DNA hypomethylation define poorly prognostic pediatric posterior fossa ependymomas. <i>Science Translational Medicine</i> , 2016 , 8, 366ra161	17.5	109
339	The lncRNA landscape of breast cancer reveals a role for DSCAM-AS1 in breast cancer progression. <i>Nature Communications</i> , 2016 , 7, 12791	17.4	152
338	Urine TMPRSS2:ERG Plus PCA3 for Individualized Prostate Cancer Risk Assessment. <i>European Urology</i> , 2016 , 70, 45-53	10.2	228
337	The Potential of MicroRNAs as Prostate Cancer Biomarkers. <i>European Urology</i> , 2016 , 70, 312-22	10.2	169
336	Mechanistic Support for Combined MET and AR Blockade in Castration-Resistant Prostate Cancer. <i>Neoplasia</i> , 2016 , 18, 1-9	6.4	19
335	BET Bromodomain Inhibitors Enhance Efficacy and Disrupt Resistance to AR Antagonists in the Treatment of Prostate Cancer. <i>Molecular Cancer Research</i> , 2016 , 14, 324-31	6.6	120
334	KRAS Engages AGO2 to Enhance Cellular Transformation. <i>Cell Reports</i> , 2016 , 14, 1448-1461	10.6	27

333	Prognostic Value of Percent Gleason Grade 4 at Prostate Biopsy in Predicting Prostatectomy Pathology and Recurrence. <i>Journal of Urology</i> , 2016 , 196, 405-11	2.5	67
332	Expression of PDL1 (B7-H1) Before and After Neoadjuvant Chemotherapy in Urothelial Carcinoma. <i>European Urology Focus</i> , 2016 , 1, 265-268	5.1	31
331	Overexpression of the Long Non-coding RNA SCHLAP1 Independently Predicts Lethal Prostate Cancer. <i>European Urology</i> , 2016 , 70, 549-552	10.2	98
330	De novo dominant ASXL3 mutations alter H2A deubiquitination and transcription in Bainbridge-Ropers syndrome. <i>Human Molecular Genetics</i> , 2016 , 25, 597-608	5.6	43
329	Germline Findings in Tumor-Only Sequencing: Points to Consider for Clinicians and Laboratories. <i>Journal of the National Cancer Institute</i> , 2016 , 108,	9.7	63
328	ESR1 Mutations in Circulating Plasma Tumor DNA from Metastatic Breast Cancer Patients. <i>Clinical Cancer Research</i> , 2016 , 22, 993-9	12.9	129
327	Cancer mediates effector T cell dysfunction by targeting microRNAs and EZH2 via glycolysis restriction. <i>Nature Immunology</i> , 2016 , 17, 95-103	19.1	234
326	The bright side of dark matter: lncRNAs in cancer. <i>Journal of Clinical Investigation</i> , 2016 , 126, 2775-82	15.9	296
325	Non-coding RNA LINC00857 is predictive of poor patient survival and promotes tumor progression via cell cycle regulation in lung cancer. <i>Oncotarget</i> , 2016 , 7, 11487-99	3.3	42
324	A comparative assessment of clinical whole exome and transcriptome profiling across sequencing centers: implications for precision cancer medicine. <i>Oncotarget</i> , 2016 , 7, 52888-52899	3.3	14
323	PDCT-03. CLINICALLY INTEGRATED SEQUENCING IN THE MANAGEMENT OF CHILDREN WITH HIGH-RISK BRAIN TUMORS. <i>Neuro-Oncology</i> , 2016 , 18, vi145-vi146	1	
322	Heat Shock Protein Beta-1 Modifies Anterior to Posterior Purkinje Cell Vulnerability in a Mouse Model of Niemann-Pick Type C Disease. <i>PLoS Genetics</i> , 2016 , 12, e1006042	6	15
321	Concurrent nuclear ERG and MYC protein overexpression defines a subset of locally advanced prostate cancer: Potential opportunities for synergistic targeted therapeutics. <i>Prostate</i> , 2016 , 76, 845-53	4.2	6
320	Inherited DNA-Repair Gene Mutations in Men with Metastatic Prostate Cancer. <i>New England Journal of Medicine</i> , 2016 , 375, 443-53	59.2	791
319	Inflammation-Induced Oxidative Stress Mediates Gene Fusion Formation in Prostate Cancer. <i>Cell Reports</i> , 2016 , 17, 2620-2631	10.6	52
318	Identification and Validation of PCAT14 as Prognostic Biomarker in Prostate Cancer. <i>Neoplasia</i> , 2016 , 18, 489-99	6.4	37
317	Comparative analysis of circulating tumor DNA stability In KEDTA, Streck, and CellSave blood collection tubes. <i>Clinical Biochemistry</i> , 2016 , 49, 1354-1360	3.5	141
316	Clinical Sequencing Exploratory Research Consortium: Accelerating Evidence-Based Practice of Genomic Medicine. <i>American Journal of Human Genetics</i> , 2016 , 98, 1051-1066	11	107

315	Biallelic Alteration and Dysregulation of the Hippo Pathway in Mucinous Tubular and Spindle Cell Carcinoma of the Kidney. <i>Cancer Discovery</i> , 2016 , 6, 1258-1266	24.4	48
314	Prostatic Adenocarcinoma With Hormone Exposure Related Changes in a Patient With Hepatic Cirrhosis - Value of Autopsy in a Case Report. <i>Urology Case Reports</i> , 2016 , 9, 37-40	0.5	
313	Role of BET proteins in castration-resistant prostate cancer. <i>Drug Discovery Today: Technologies</i> , 2016 , 19, 29-38	7.1	12
312	Translating cancer genomes and transcriptomes for precision oncology. <i>Ca-A Cancer Journal for Clinicians</i> , 2016 , 66, 75-88	220.7	108
311	A subset of solitary fibrous tumors express nuclear PAX8 and PAX2: a potential diagnostic pitfall. <i>Histology and Histopathology</i> , 2016 , 31, 223-30	1.4	6
310	The landscape of long noncoding RNAs in the human transcriptome. <i>Nature Genetics</i> , 2015 , 47, 199-208	36.3	1789
309	rSeqNP: a non-parametric approach for detecting differential expression and splicing from RNA-Seq data. <i>Bioinformatics</i> , 2015 , 31, 2222-4	7.2	11
308	Development and validation of a scalable next-generation sequencing system for assessing relevant somatic variants in solid tumors. <i>Neoplasia</i> , 2015 , 17, 385-99	6.4	156
307	Impact of tertiary Gleason pattern 5 on prostate cancer aggressiveness: Lessons from a contemporary single institution radical prostatectomy series. <i>Asian Journal of Urology</i> , 2015 , 2, 53-58	2.7	10
306	Galanin modulates the neural niche to favour perineural invasion in head and neck cancer. <i>Nature Communications</i> , 2015 , 6, 6885	17.4	53
305	Molecular and immunohistochemical characterization reveals novel BRAF mutations in metanephric adenoma. <i>American Journal of Surgical Pathology</i> , 2015 , 39, 549-57	6.7	35
304	Targeting the MLL complex in castration-resistant prostate cancer. <i>Nature Medicine</i> , 2015 , 21, 344-52	50.5	126
303	aBETting therapeutic resistance by Wnt signaling. <i>Cell Research</i> , 2015 , 25, 1187-8	24.7	6
302	DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer. <i>New England Journal of Medicine</i> , 2015 , 373, 1697-708	59.2	1345
301	Long noncoding RNAs in cancer: from function to translation. <i>Trends in Cancer</i> , 2015 , 1, 93-109	12.5	179
300	The use of exome capture RNA-seq for highly degraded RNA with application to clinical cancer sequencing. <i>Genome Research</i> , 2015 , 25, 1372-81	9.7	112
299	Urothelial Cancer With Occult Bone Marrow Metastases and Isolated Thrombocytopenia. <i>Urology Case Reports</i> , 2015 , 3, 98-100	0.5	1
298	Clinicopathologic characteristics of anterior prostate cancer (APC), including correlation with previous biopsy pathology. <i>Medical Oncology</i> , 2015 , 32, 249	3.7	5

297	Integrative Clinical Sequencing in the Management of Refractory or Relapsed Cancer in Youth. <i>JAMA - Journal of the American Medical Association</i> , 2015 , 314, 913-25	27.4	257
296	The Distinctive Mutational Spectra of Polyomavirus-Negative Merkel Cell Carcinoma. <i>Cancer Research</i> , 2015 , 75, 3720-3727	10.1	196
295	Reply to Carsten Stephan, Henning Cammann, and Klaus Jung Letter to the Editor re: Scott A. Tomlins, John R. Day, Robert J. Lonigro, et al. Urine TMPRSS2:ERG Plus PCA3 for Individualized Prostate Cancer Risk Assessment. <i>Eur Urol</i> . In press. http://dx.doi.org/10.1016/j.eururo.2015.04.039 . <i>European Urology</i> , 2015 , 68, e108	10.2	11
294	Molecular profiling of ETS gene rearrangements in patients with prostate cancer registered in REDEEM clinical trial. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2015 , 33, 108.e5-13	2.8	3
293	Molecular profiling of ETS and non-ETS aberrations in prostate cancer patients from northern India. <i>Prostate</i> , 2015 , 75, 1051-62	4.2	15
292	Landscape of gene fusions in epithelial cancers: seq and ye shall find. <i>Genome Medicine</i> , 2015 , 7, 129	14.4	102
291	Role and regulation of coordinately expressed de novo purine biosynthetic enzymes PPAT and PAICS in lung cancer. <i>Oncotarget</i> , 2015 , 6, 23445-61	3.3	49
290	Integrative clinical genomics of advanced prostate cancer. <i>Cell</i> , 2015 , 161, 1215-1228	56.2	1765
289	The landscape of antisense gene expression in human cancers. <i>Genome Research</i> , 2015 , 25, 1068-79	9.7	110
288	Coactivator SRC-2-dependent metabolic reprogramming mediates prostate cancer survival and metastasis. <i>Journal of Clinical Investigation</i> , 2015 , 125, 1174-88	15.9	63
287	Genome-Wide Binding Studies of Acetyl-STAT3 Demonstrates a Novel Regulatory Pathway in Dendritic Cells. <i>Blood</i> , 2015 , 126, 647-647	2.2	
286	Papillary renal cell carcinoma revisited: a comprehensive histomorphologic study with outcome correlations. <i>Human Pathology</i> , 2014 , 45, 1139-46	3.7	21
285	Evaluation of tissue PCA3 expression in prostate cancer by RNA in situ hybridization--a correlative study with urine PCA3 and TMPRSS2-ERG. <i>Modern Pathology</i> , 2014 , 27, 609-20	9.8	32
284	PCAT-1, a long noncoding RNA, regulates BRCA2 and controls homologous recombination in cancer. <i>Cancer Research</i> , 2014 , 74, 1651-60	10.1	204
283	Metabolomic profiling identifies biochemical pathways associated with castration-resistant prostate cancer. <i>Journal of Proteome Research</i> , 2014 , 13, 1088-100	5.6	45
282	The central role of EED in the orchestration of polycomb group complexes. <i>Nature Communications</i> , 2014 , 5, 3127	17.4	91
281	HRAS mutations are frequent in inverted urothelial neoplasms. <i>Human Pathology</i> , 2014 , 45, 1957-65	3.7	36
280	Prostate cancer with Paneth cell-like neuroendocrine differentiation has recognizable histomorphology and harbors AURKA gene amplification. <i>Human Pathology</i> , 2014 , 45, 2136-43	3.7	22

279	TRIP13 promotes error-prone nonhomologous end joining and induces chemoresistance in head and neck cancer. <i>Nature Communications</i> , 2014 , 5, 4527	17.4	81
278	Therapeutic targeting of BET bromodomain proteins in castration-resistant prostate cancer. <i>Nature</i> , 2014 , 510, 278-82	50.4	650
277	The lncRNA PCAT29 inhibits oncogenic phenotypes in prostate cancer. <i>Molecular Cancer Research</i> , 2014 , 12, 1081-7	6.6	103
276	BETs abet Tam-R in ER-positive breast cancer. <i>Cell Research</i> , 2014 , 24, 899-900	24.7	9
275	KRAS protein stability is regulated through SMURF2: UBC5 complex-mediated ETrCP1 degradation. <i>Neoplasia</i> , 2014 , 16, 115-28	6.4	58
274	RNA identity crisis: hepatitis B walks the LINE. <i>Cancer Cell</i> , 2014 , 25, 259-60	24.3	5
273	The lncRNAs PCGEM1 and PRNCR1 are not implicated in castration resistant prostate cancer. <i>Oncotarget</i> , 2014 , 5, 1434-8	3.3	84
272	Prostate cancer cell-stromal cell crosstalk via FGFR1 mediates antitumor activity of dovitinib in bone metastases. <i>Science Translational Medicine</i> , 2014 , 6, 252ra122	17.5	71
271	Consensus statement with recommendations on active surveillance inclusion criteria and definition of progression in men with localized prostate cancer: the critical role of the pathologist. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2014 , 465, 623-8	5.1	33
270	A novel RNA in situ hybridization assay for the long noncoding RNA SCHLAP1 predicts poor clinical outcome after radical prostatectomy in clinically localized prostate cancer. <i>Neoplasia</i> , 2014 , 16, 1121-7	6.4	71
269	The long non-coding RNA PCAT-1 promotes prostate cancer cell proliferation through cMyc. <i>Neoplasia</i> , 2014 , 16, 900-8	6.4	187
268	The critical role of the pathologist in determining eligibility for active surveillance as a management option in patients with prostate cancer: consensus statement with recommendations supported by the College of American Pathologists, International Society of Urological Pathology, Association of Directors of Anatomic and Surgical Pathology, the New Zealand Society of	5	99
267	Activating mutations of the oncogene EZH2 in cutaneous melanoma revealed by next generation sequencing. <i>Human Pathology: Case Reports</i> , 2014 , 1, 21-28	0.2	7
266	Frequent discordance between ERG gene rearrangement and ERG protein expression in a rapid autopsy cohort of patients with lethal, metastatic, castration-resistant prostate cancer. <i>Prostate</i> , 2014 , 74, 1199-208	4.2	25
265	Transcriptome meta-analysis of lung cancer reveals recurrent aberrations in NRG1 and Hippo pathway genes. <i>Nature Communications</i> , 2014 , 5, 5893	17.4	100
264	RNA biomarkers associated with metastatic progression in prostate cancer: a multi-institutional high-throughput analysis of SCHLAP1. <i>Lancet Oncology, The</i> , 2014 , 15, 1469-1480	21.7	192
263	RNA-Seq accurately identifies cancer biomarker signatures to distinguish tissue of origin. <i>Neoplasia</i> , 2014 , 16, 918-27	6.4	25
262	Estrogen receptor mutations and their role in breast cancer progression. <i>Breast Cancer Research</i> , 2014 , 16, 494	8.3	69

261	Immunohistochemical staining characteristics of nephrogenic adenoma using the PIN-4 cocktail (p63, AMACR, and CK903) and GATA-3. <i>American Journal of Surgical Pathology</i> , 2014 , 38, 1664-71	6.7	21
260	HOXB13 G84E-related familial prostate cancers: a clinical, histologic, and molecular survey. <i>American Journal of Surgical Pathology</i> , 2014 , 38, 615-26	6.7	35
259	Molecular pathways: targeting ETS gene fusions in cancer. <i>Clinical Cancer Research</i> , 2014 , 20, 4442-8	12.9	44
258	Clinical tumor sequencing: an incidental casualty of the American College of Medical Genetics and Genomics recommendations for reporting of incidental findings. <i>Journal of Clinical Oncology</i> , 2014 , 32, 2203-5	2.2	31
257	Antibody-independent targeted quantification of TMPRSS2-ERG fusion protein products in prostate cancer. <i>Molecular Oncology</i> , 2014 , 8, 1169-80	7.9	20
256	Primary urethral clear-cell adenocarcinoma: comprehensive analysis by surgical pathology, cytopathology, and next-generation sequencing. <i>American Journal of Pathology</i> , 2014 , 184, 584-91	5.8	34
255	The miR-124-prolyl hydroxylase P4HA1-MMP1 axis plays a critical role in prostate cancer progression. <i>Oncotarget</i> , 2014 , 5, 6654-69	3.3	70
254	HR-MAS NMR tissue metabolomic signatures cross-validated by mass spectrometry distinguish bladder cancer from benign disease. <i>Journal of Proteome Research</i> , 2013 , 12, 3519-28	5.6	42
253	Targeted radiosensitization of ETS fusion-positive prostate cancer through PARP1 inhibition. <i>Neoplasia</i> , 2013 , 15, 1207-17	6.4	39
252	The role of sarcosine metabolism in prostate cancer progression. <i>Neoplasia</i> , 2013 , 15, 491-501	6.4	111
251	Comprehensive Analysis of ETS Family Members in Melanoma by Fluorescence In Situ Hybridization Reveals Recurrent ETV1 Amplification. <i>Translational Oncology</i> , 2013 , 6, 405-12	4.9	10
250	The long noncoding RNA SCHLAP1 promotes aggressive prostate cancer and antagonizes the SWI/SNF complex. <i>Nature Genetics</i> , 2013 , 45, 1392-8	36.3	515
249	Identification of targetable FGFR gene fusions in diverse cancers. <i>Cancer Discovery</i> , 2013 , 3, 636-47	24.4	511
248	Identification of recurrent NAB2-STAT6 gene fusions in solitary fibrous tumor by integrative sequencing. <i>Nature Genetics</i> , 2013 , 45, 180-5	36.3	514
247	Activating ESR1 mutations in hormone-resistant metastatic breast cancer. <i>Nature Genetics</i> , 2013 , 45, 1446-51	36.3	742
246	Advancing precision medicine for prostate cancer through genomics. <i>Journal of Clinical Oncology</i> , 2013 , 31, 1866-73	2.2	70
245	Combining urinary detection of TMPRSS2:ERG and PCA3 with serum PSA to predict diagnosis of prostate cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2013 , 31, 566-71	2.8	160
244	MicroRNA expression patterns in indeterminate inflammatory bowel disease. <i>Modern Pathology</i> , 2013 , 26, 148-54	9.8	23

243	Characterization of the EZH2-MMSET histone methyltransferase regulatory axis in cancer. <i>Molecular Cell</i> , 2013 , 49, 80-93	17.6	110
242	Noncoding RNAs and cancer. <i>Cell</i> , 2013 , 153, 9-10	56.2	35
241	Novel dual-color immunohistochemical methods for detecting ERG-PTEN and ERG-SPINK1 status in prostate carcinoma. <i>Modern Pathology</i> , 2013 , 26, 835-48	9.8	42
240	HIV infection reveals widespread expansion of novel centromeric human endogenous retroviruses. <i>Genome Research</i> , 2013 , 23, 1505-13	9.7	51
239	Next-generation sequencing identifies the Danforth β short tail mouse mutation as a retrotransposon insertion affecting Ptf1a expression. <i>PLoS Genetics</i> , 2013 , 9, e1003205	6	20
238	Usefulness of a monoclonal ERG/FLI1 antibody for immunohistochemical discrimination of Ewing family tumors. <i>American Journal of Clinical Pathology</i> , 2013 , 139, 771-9	1.9	28
237	Outlier kinase expression by RNA sequencing as targets for precision therapy. <i>Cancer Discovery</i> , 2013 , 3, 280-93	24.4	33
236	Recurrent reciprocal RNA chimera involving YPEL5 and PPP1CB in chronic lymphocytic leukemia. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2013 , 110, 3035-40	11.5	35
235	Allogeneic T cell responses are regulated by a specific miRNA-mRNA network. <i>Journal of Clinical Investigation</i> , 2013 , 123, 4739-54	15.9	28
234	Circulating microRNA profiling identifies a subset of metastatic prostate cancer patients with evidence of cancer-associated hypoxia. <i>PLoS ONE</i> , 2013 , 8, e69239	3.7	124
233	The Histone Methyltransferase Ezh2 Is a Crucial Epigenetic Regulator Of Allogeneic T Cell Responses and Graft-Versus-Host Disease In Mice. <i>Blood</i> , 2013 , 122, 137-137	2.2	
232	Inhibition of histone methylation arrests ongoing graft-versus-host disease in mice by selectively inducing apoptosis of alloreactive effector T cells. <i>Blood</i> , 2012 , 119, 1274-82	2.2	54
231	Androgen receptor activation results in metabolite signatures of an aggressive prostate cancer phenotype: an NMR-based metabolomics study. <i>Metabolomics</i> , 2012 , 8, 1026-1036	4.7	13
230	Role of transcriptional corepressor CtBP1 in prostate cancer progression. <i>Neoplasia</i> , 2012 , 14, 905-14	6.4	49
229	Gene fusions associated with recurrent amplicons represent a class of passenger aberrations in breast cancer. <i>Neoplasia</i> , 2012 , 14, 702-8	6.4	50
228	PARP-1 inhibition as a targeted strategy to treat Ewing β sarcoma. <i>Cancer Research</i> , 2012 , 72, 1608-13	10.1	203
227	Dual roles of PARP-1 promote cancer growth and progression. <i>Cancer Discovery</i> , 2012 , 2, 1134-49	24.4	260
226	Systematic, evidence-based discovery of biomarkers at the NCI. <i>Clinical and Experimental Metastasis</i> , 2012 , 29, 645-52	4.7	21

225	Pathway-directed weighted testing procedures for the integrative analysis of gene expression and metabolomic data. <i>Genomics</i> , 2012 , 99, 265-74	4.3	8
224	Beyond PSA: the next generation of prostate cancer biomarkers. <i>Science Translational Medicine</i> , 2012 , 4, 127rv3	17.5	313
223	The mutational landscape of lethal castration-resistant prostate cancer. <i>Nature</i> , 2012 , 487, 239-43	50.4	1708
222	Delineating metabolic signatures of head and neck squamous cell carcinoma: phospholipase A2, a potential therapeutic target. <i>International Journal of Biochemistry and Cell Biology</i> , 2012 , 44, 1852-61	5.6	69
221	Analysis of the tau-associated proteome reveals that exchange of Hsp70 for Hsp90 is involved in tau degradation. <i>ACS Chemical Biology</i> , 2012 , 7, 1677-86	4.9	53
220	Expressed pseudogenes in the transcriptional landscape of human cancers. <i>Cell</i> , 2012 , 149, 1622-34	56.2	203
219	Variable reference alignment: an improved peak alignment protocol for NMR spectral data with large intersample variation. <i>Analytical Chemistry</i> , 2012 , 84, 5372-9	7.8	25
218	Correlation of urine TMPRSS2:ERG and PCA3 to ERG+ and total prostate cancer burden. <i>American Journal of Clinical Pathology</i> , 2012 , 138, 685-96	1.9	64
217	Antibody-based detection of ERG rearrangements in prostate core biopsies, including diagnostically challenging cases: ERG staining in prostate core biopsies. <i>Archives of Pathology and Laboratory Medicine</i> , 2012 , 136, 935-46	5	78
216	Common structural and epigenetic changes in the genome of castration-resistant prostate cancer. <i>Cancer Research</i> , 2012 , 72, 616-25	10.1	97
215	Next generation sequencing of prostate cancer from a patient identifies a deficiency of methylthioadenosine phosphorylase, an exploitable tumor target. <i>Molecular Cancer Therapeutics</i> , 2012 , 11, 775-83	6.1	30
214	SLC45A3-ELK4 chimera in prostate cancer: spotlight on cis-splicing. <i>Cancer Discovery</i> , 2012 , 2, 582-5	24.4	34
213	Insights into Chinese prostate cancer with RNA-seq. <i>Cell Research</i> , 2012 , 22, 786-8	24.7	4
212	A dual role for receptor-interacting protein kinase 2 (RIP2) kinase activity in nucleotide-binding oligomerization domain 2 (NOD2)-dependent autophagy. <i>Journal of Biological Chemistry</i> , 2012 , 287, 25565-76	5.4	62
211	Identification of functionally active, low frequency copy number variants at 15q21.3 and 12q21.31 associated with prostate cancer risk. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2012 , 109, 6686-91	11.5	42
210	The enzymatic activity of apoptosis-inducing factor supports energy metabolism benefiting the growth and invasiveness of advanced prostate cancer cells. <i>Journal of Biological Chemistry</i> , 2012 , 287, 43862-75	5.4	14
209	Genetic and epigenetic loss of microRNA-31 leads to feed-forward expression of EZH2 in melanoma. <i>Oncotarget</i> , 2012 , 3, 1011-25	3.3	113
208	Histone Methyltransferase Ezh2 Controls T-Cell Immunity by Regulating Bioenergetic Metabolism. <i>Blood</i> , 2012 , 120, 953-953	2.2	

207	Detection of somatic copy number alterations in cancer using targeted exome capture sequencing. <i>Neoplasia</i> , 2011 , 13, 1019-25	6.4	65
206	Therapeutic targeting of SPINK1-positive prostate cancer. <i>Science Translational Medicine</i> , 2011 , 3, 72ra17	17.5	120
205	Transcriptome sequencing across a prostate cancer cohort identifies PCAT-1, an unannotated lincRNA implicated in disease progression. <i>Nature Biotechnology</i> , 2011 , 29, 742-9	44.5	824
204	Magic angle spinning NMR-based metabolic profiling of head and neck squamous cell carcinoma tissues. <i>Journal of Proteome Research</i> , 2011 , 10, 5232-41	5.6	87
203	Molecular characterization of neuroendocrine prostate cancer and identification of new drug targets. <i>Cancer Discovery</i> , 2011 , 1, 487-95	24.4	550
202	Targeting of microRNA-142-3p in dendritic cells regulates endotoxin-induced mortality. <i>Blood</i> , 2011 , 117, 6172-83	2.2	116
201	Disruptive events in the life of prostate cancer. <i>Cancer Cell</i> , 2011 , 19, 301-3	24.3	18
200	Mechanistic rationale for inhibition of poly(ADP-ribose) polymerase in ETS gene fusion-positive prostate cancer. <i>Cancer Cell</i> , 2011 , 19, 664-78	24.3	342
199	Coordinated regulation of polycomb group complexes through microRNAs in cancer. <i>Cancer Cell</i> , 2011 , 20, 187-99	24.3	176
198	The emergence of lncRNAs in cancer biology. <i>Cancer Discovery</i> , 2011 , 1, 391-407	24.4	1384
197	Personalized oncology through integrative high-throughput sequencing: a pilot study. <i>Science Translational Medicine</i> , 2011 , 3, 111ra121	17.5	452
196	Common gene rearrangements in prostate cancer. <i>Journal of Clinical Oncology</i> , 2011 , 29, 3659-68	2.2	231
195	Discovery of non-ETS gene fusions in human prostate cancer using next-generation RNA sequencing. <i>Genome Research</i> , 2011 , 21, 56-67	9.7	156
194	Functionally recurrent rearrangements of the MAST kinase and Notch gene families in breast cancer. <i>Nature Medicine</i> , 2011 , 17, 1646-51	50.5	262
193	Copy number and targeted mutational analysis reveals novel somatic events in metastatic prostate tumors. <i>Genome Research</i> , 2011 , 21, 47-55	9.7	134
192	Characterization of bone metastases from rapid autopsies of prostate cancer patients. <i>Clinical Cancer Research</i> , 2011 , 17, 3924-32	12.9	60
191	Deep sequencing reveals distinct patterns of DNA methylation in prostate cancer. <i>Genome Research</i> , 2011 , 21, 1028-41	9.7	144
190	TMPRSS2-ERG-mediated feed-forward regulation of wild-type ERG in human prostate cancers. <i>Cancer Research</i> , 2011 , 71, 5387-92	10.1	40

189	Urine TMPRSS2:ERG fusion transcript stratifies prostate cancer risk in men with elevated serum PSA. <i>Science Translational Medicine</i> , 2011 , 3, 94ra72	17.5	281
188	The DEK oncoprotein is a Su(var) that is essential to heterochromatin integrity. <i>Genes and Development</i> , 2011 , 25, 673-8	12.6	65
187	Characterization of KRAS rearrangements in metastatic prostate cancer. <i>Cancer Discovery</i> , 2011 , 1, 35-43	24.4	83
186	A comparison of single molecule and amplification based sequencing of cancer transcriptomes. <i>PLoS ONE</i> , 2011 , 6, e17305	3.7	42
185	Inhibition of Histone Methylation Arrests Ongoing Graft-Versus-Host Diseases in Mice by Selectively Inducing Apoptosis of Alloreactive Effector T Cells. <i>Blood</i> , 2011 , 118, 820-820	2.2	
184	Rearrangements of the RAF kinase pathway in prostate cancer, gastric cancer and melanoma. <i>Nature Medicine</i> , 2010 , 16, 793-8	50.5	382
183	Triggers for genomic rearrangements: insights into genomic, cellular and environmental influences. <i>Nature Reviews Genetics</i> , 2010 , 11, 819-29	30.1	106
182	"Topological significance" analysis of gene expression and proteomic profiles from prostate cancer cells reveals key mechanisms of androgen response. <i>PLoS ONE</i> , 2010 , 5, e10936	3.7	29
181	Quantitative proteomic profiling of prostate cancer reveals a role for miR-128 in prostate cancer. <i>Molecular and Cellular Proteomics</i> , 2010 , 9, 298-312	7.6	96
180	On the detection and refinement of transcription factor binding sites using ChIP-Seq data. <i>Nucleic Acids Research</i> , 2010 , 38, 2154-67	20.1	82
179	The role of YAP transcription coactivator in regulating stem cell self-renewal and differentiation. <i>Genes and Development</i> , 2010 , 24, 1106-18	12.6	512
178	Nrdp1-mediated regulation of ErbB3 expression by the androgen receptor in androgen-dependent but not castrate-resistant prostate cancer cells. <i>Cancer Research</i> , 2010 , 70, 5994-6003	10.1	43
177	Antibody-based detection of ERG rearrangement-positive prostate cancer. <i>Neoplasia</i> , 2010 , 12, 590-8	6.4	281
176	ERG cooperates with androgen receptor in regulating trefoil factor 3 in prostate cancer disease progression. <i>Neoplasia</i> , 2010 , 12, 1031-40	6.4	46
175	Chromosomal aberrations in solid tumors. <i>Progress in Molecular Biology and Translational Science</i> , 2010 , 95, 55-94	4	19
174	ETS gene aberrations in atypical cribriform lesions of the prostate: Implications for the distinction between intraductal carcinoma of the prostate and cribriform high-grade prostatic intraepithelial neoplasia. <i>American Journal of Surgical Pathology</i> , 2010 , 34, 478-85	6.7	74
173	Re: Florian Jentzmik, Carsten Stephan, Kurt Miller, et al. Sarcosine in urine after digital rectal examination fails as a marker in prostate cancer detection and identification of aggressive tumours. <i>Eur Urol</i> 2010;58:12-8. <i>European Urology</i> , 2010 , 58, e29-30; author reply e31-2	10.2	16
172	An integrated network of androgen receptor, polycomb, and TMPRSS2-ERG gene fusions in prostate cancer progression. <i>Cancer Cell</i> , 2010 , 17, 443-54	24.3	640

171	Development of selected reaction monitoring-MS methodology to measure peptide biomarkers in prostate cancer. <i>Proteomics</i> , 2010 , 10, 3506-14	4.8	20
170	Exploring clinical associations using PomicsPbased enrichment analyses. <i>PLoS ONE</i> , 2009 , 4, e5203	3.7	42
169	Nuclear versus cytoplasmic localization of filamin A in prostate cancer: immunohistochemical correlation with metastases. <i>Clinical Cancer Research</i> , 2009 , 15, 788-96	12.9	100
168	Development of a multiplex quantitative PCR signature to predict progression in non-muscle-invasive bladder cancer. <i>Cancer Research</i> , 2009 , 69, 3810-8	10.1	32
167	Induced chromosomal proximity and gene fusions in prostate cancer. <i>Science</i> , 2009 , 326, 1230	33.3	299
166	Melanoma proliferation and chemoresistance controlled by the DEK oncogene. <i>Cancer Research</i> , 2009 , 69, 6405-13	10.1	110
165	Prevalence of TMPRSS2-ERG fusion prostate cancer among men undergoing prostate biopsy in the United States. <i>Clinical Cancer Research</i> , 2009 , 15, 4706-11	12.9	181
164	AGTR1 overexpression defines a subset of breast cancer and confers sensitivity to losartan, an AGTR1 antagonist. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2009 , 106, 10284-9	11.5	111
163	Chimeric transcript discovery by paired-end transcriptome sequencing. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2009 , 106, 12353-8	11.5	275
162	ETS gene fusions in prostate cancer: from discovery to daily clinical practice. <i>European Urology</i> , 2009 , 56, 275-86	10.2	279
161	Fluorescence in situ hybridization study shows association of PTEN deletion with ERG rearrangement during prostate cancer progression. <i>Modern Pathology</i> , 2009 , 22, 1083-93	9.8	190
160	Characterization of ETS gene aberrations in select histologic variants of prostate carcinoma. <i>Modern Pathology</i> , 2009 , 22, 1176-85	9.8	77
159	Transcriptome sequencing to detect gene fusions in cancer. <i>Nature</i> , 2009 , 458, 97-101	50.4	709
158	Tomlins et al. reply. <i>Nature</i> , 2009 , 457, E2-E3	50.4	5
157	Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression. <i>Nature</i> , 2009 , 457, 910-4	50.4	1636
156	An integrative approach to reveal driver gene fusions from paired-end sequencing data in cancer. <i>Nature Biotechnology</i> , 2009 , 27, 1005-11	44.5	63
155	Treatment-dependent androgen receptor mutations in prostate cancer exploit multiple mechanisms to evade therapy. <i>Cancer Research</i> , 2009 , 69, 4434-42	10.1	162
154	Current affairs in quantitative targeted proteomics: multiple reaction monitoring-mass spectrometry. <i>Briefings in Functional Genomics & Proteomics</i> , 2009 , 8, 145-57		95

153	Pathway biomarker profiling of localized and metastatic human prostate cancer reveal metastatic and prognostic signatures. <i>Journal of Proteome Research</i> , 2009 , 8, 3044-54	5.6	51
152	New class of microRNA targets containing simultaneous 5PUTR and 3PUTR interaction sites. <i>Genome Research</i> , 2009 , 19, 1175-83	9.7	346
151	Applications of genetic programming in cancer research. <i>International Journal of Biochemistry and Cell Biology</i> , 2009 , 41, 405-13	5.6	21
150	Androgen receptor regulates a distinct transcription program in androgen-independent prostate cancer. <i>Cell</i> , 2009 , 138, 245-56	56.2	691
149	Oncogenic gene fusions in epithelial carcinomas. <i>Current Opinion in Genetics and Development</i> , 2009 , 19, 82-91	4.9	60
148	A FIRE-y PAGE in the computational analysis of cancer profiles. <i>Molecular Cell</i> , 2009 , 36, 732-3	17.6	
147	RHAMM (CD168) is overexpressed at the protein level and may constitute an immunogenic antigen in advanced prostate cancer disease. <i>Neoplasia</i> , 2009 , 11, 956-63	6.4	58
146	The discovery of common recurrent transmembrane protease serine 2 (TMPRSS2)-erythroblastosis virus E26 transforming sequence (ETS) gene fusions in prostate cancer: significance and clinical implications. <i>Advances in Anatomic Pathology</i> , 2009 , 16, 145-53	5.1	41
145	Genomic outlier profile analysis: mixture models, null hypotheses, and nonparametric estimation. <i>Biostatistics</i> , 2009 , 10, 60-9	3.7	24
144	Proteomic interrogation of androgen action in prostate cancer cells reveals roles of aminoacyl tRNA synthetases. <i>PLoS ONE</i> , 2009 , 4, e7075	3.7	39
143	The discovery and application of gene fusions in prostate cancer. <i>BJU International</i> , 2008 , 102, 276-82	5.6	29
142	The role of SPINK1 in ETS rearrangement-negative prostate cancers. <i>Cancer Cell</i> , 2008 , 13, 519-28	24.3	254
141	CXCL5 promotes prostate cancer progression. <i>Neoplasia</i> , 2008 , 10, 244-54	6.4	103
140	Recurrent gene fusions in prostate cancer. <i>Nature Reviews Cancer</i> , 2008 , 8, 497-511	31.3	554
139	Inhibition of CCN6 (Wnt-1-induced signaling protein 3) down-regulates E-cadherin in the breast epithelium through induction of snail and ZEB1. <i>American Journal of Pathology</i> , 2008 , 172, 893-904	5.8	56
138	Role of the TMPRSS2-ERG gene fusion in prostate cancer. <i>Neoplasia</i> , 2008 , 10, 177-88	6.4	522
137	Golgi protein GOLM1 is a tissue and urine biomarker of prostate cancer. <i>Neoplasia</i> , 2008 , 10, 1285-94	6.4	74
136	A transcriptional fingerprint of estrogen in human breast cancer predicts patient survival. <i>Neoplasia</i> , 2008 , 10, 79-88	6.4	30

135	EML4-ALK fusion lung cancer: a rare acquired event. <i>Neoplasia</i> , 2008 , 10, 298-302	6.4	201
134	Genomic loss of microRNA-101 leads to overexpression of histone methyltransferase EZH2 in cancer. <i>Science</i> , 2008 , 322, 1695-9	33.3	888
133	A first-generation multiplex biomarker analysis of urine for the early detection of prostate cancer. <i>Cancer Research</i> , 2008 , 68, 645-9	10.1	330
132	Characterization of TMPRSS2-ETS gene aberrations in androgen-independent metastatic prostate cancer. <i>Cancer Research</i> , 2008 , 68, 3584-90	10.1	220
131	A fluorescence in situ hybridization screen for E26 transformation-specific aberrations: identification of DDX5-ETV4 fusion protein in prostate cancer. <i>Cancer Research</i> , 2008 , 68, 7629-37	10.1	127
130	Humoral response profiling reveals pathways to prostate cancer progression. <i>Molecular and Cellular Proteomics</i> , 2008 , 7, 600-11	7.6	45
129	Characterization of TMPRSS2:ETV5 and SLC45A3:ETV5 gene fusions in prostate cancer. <i>Cancer Research</i> , 2008 , 68, 73-80	10.1	212
128	Estrogen-dependent signaling in a molecularly distinct subclass of aggressive prostate cancer. <i>Journal of the National Cancer Institute</i> , 2008 , 100, 815-25	9.7	251
127	TEAD mediates YAP-dependent gene induction and growth control. <i>Genes and Development</i> , 2008 , 22, 1962-71	12.6	1534
126	AZGP1 autoantibody predicts survival and histone deacetylase inhibitors increase expression in lung adenocarcinoma. <i>Journal of Thoracic Oncology</i> , 2008 , 3, 1236-44	8.9	41
125	Fas-mediated T cell deletion potentiates tumor antigen-specific tolerance in a mouse model of prostate cancer. <i>Cancer Immunology, Immunotherapy</i> , 2008 , 57, 1357-65	7.4	4
124	CCL2 induces prostate cancer transendothelial cell migration via activation of the small GTPase Rac. <i>Journal of Cellular Biochemistry</i> , 2008 , 104, 1587-97	4.7	38
123	KLF6-SV1 overexpression accelerates human and mouse prostate cancer progression and metastasis. <i>Journal of Clinical Investigation</i> , 2008 , 118, 2711-21	15.9	89
122	An expression signature of estrogen-regulated genes predicts disease-free survival in tamoxifen-treated patients better than progesterone receptor status. <i>Transactions of the American Clinical and Climatological Association</i> , 2008 , 119, 77-90; discussion 90-2	0.9	11
121	Oncomine 3.0: genes, pathways, and networks in a collection of 18,000 cancer gene expression profiles. <i>Neoplasia</i> , 2007 , 9, 166-80	6.4	1537
120	Molecular concepts analysis links tumors, pathways, mechanisms, and drugs. <i>Neoplasia</i> , 2007 , 9, 443-54	6.4	118
119	Molecular characterization of TMPRSS2-ERG gene fusion in the NCI-H660 prostate cancer cell line: a new perspective for an old model. <i>Neoplasia</i> , 2007 , 9, 200-6	6.4	104
118	The lethal phenotype of cancer: the molecular basis of death due to malignancy. <i>Ca-A Cancer Journal for Clinicians</i> , 2007 , 57, 225-41	220.7	120

117	Feature selection and molecular classification of cancer using genetic programming. <i>Neoplasia</i> , 2007 , 9, 292-303	6.4	56
116	Empirical Bayes identification [correction of identification] of tumor progression genes from microarray data. <i>Biometrical Journal</i> , 2007 , 49, 68-77	1.5	
115	Integrative molecular concept modeling of prostate cancer progression. <i>Nature Genetics</i> , 2007 , 39, 41-51	16.3	734
114	Comprehensive assessment of TMPRSS2 and ETS family gene aberrations in clinically localized prostate cancer. <i>Modern Pathology</i> , 2007 , 20, 538-44	9.8	250
113	Distinct classes of chromosomal rearrangements create oncogenic ETS gene fusions in prostate cancer. <i>Nature</i> , 2007 , 448, 595-9	50.4	654
112	Integrative genomics analysis reveals silencing of beta-adrenergic signaling by polycomb in prostate cancer. <i>Cancer Cell</i> , 2007 , 12, 419-31	24.3	185
111	The registry case finding engine: an automated tool to identify cancer cases from unstructured, free-text pathology reports and clinical notes. <i>Journal of the American College of Surgeons</i> , 2007 , 205, 690-7	4.4	21
110	Inactivation of YAP oncoprotein by the Hippo pathway is involved in cell contact inhibition and tissue growth control. <i>Genes and Development</i> , 2007 , 21, 2747-61	12.6	1938
109	From bytes to bedside: data integration and computational biology for translational cancer research. <i>PLoS Computational Biology</i> , 2007 , 3, e12	5	48
108	Bioinformatics approaches in the study of cancer. <i>Current Molecular Medicine</i> , 2007 , 7, 133-41	2.5	56
107	Integrating biomedical knowledge to model pathways of prostate cancer progression. <i>Cell Cycle</i> , 2007 , 6, 1177-87	4.7	11
106	A polycomb repression signature in metastatic prostate cancer predicts cancer outcome. <i>Cancer Research</i> , 2007 , 67, 10657-63	10.1	270
105	Tumor cell-selective regulation of NOXA by c-MYC in response to proteasome inhibition. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2007 , 104, 19488-93	11.5	152
104	Integrative analysis of genomic aberrations associated with prostate cancer progression. <i>Cancer Research</i> , 2007 , 67, 8229-39	10.1	96
103	Autoantibody profiles reveal ubiquilin 1 as a humoral immune response target in lung adenocarcinoma. <i>Cancer Research</i> , 2007 , 67, 3461-7	10.1	76
102	TMPRSS2-ERG fusion prostate cancer: an early molecular event associated with invasion. <i>American Journal of Surgical Pathology</i> , 2007 , 31, 882-8	6.7	351
101	A hierarchical network of transcription factors governs androgen receptor-dependent prostate cancer growth. <i>Molecular Cell</i> , 2007 , 27, 380-92	17.6	526
100	Heterogeneity of TMPRSS2 gene rearrangements in multifocal prostate adenocarcinoma: molecular evidence for an independent group of diseases. <i>Cancer Research</i> , 2007 , 67, 7991-5	10.1	176

99	Of mice and men: cancer gene discovery using comparative oncogenomics. <i>Cancer Cell</i> , 2006 , 10, 2-4	24.3	9
98	Enhancing the antitumor activity of ErbB blockade with histone deacetylase (HDAC) inhibition. <i>International Journal of Cancer</i> , 2006 , 118, 1041-50	7.5	33
97	Selection and cloning of poly(rC)-binding protein 2 and Raf kinase inhibitor protein RNA activators of 2,5-Poligoadenylate synthetase from prostate cancer cells. <i>Nucleic Acids Research</i> , 2006 , 34, 6684-95	20.1	41
96	Trisomy 12-associated, t(11;14)-negative mature B-cell leukemia with gene expression profile resembling mantle cell lymphoma. <i>Leukemia and Lymphoma</i> , 2006 , 47, 121-7	1.9	3
95	TMPRSS2:ERG fusion-associated deletions provide insight into the heterogeneity of prostate cancer. <i>Cancer Research</i> , 2006 , 66, 8337-41	10.1	419
94	Nod1 acts as an intracellular receptor to stimulate chemokine production and neutrophil recruitment in vivo. <i>Journal of Experimental Medicine</i> , 2006 , 203, 203-13	16.6	173
93	A systems approach to model metastatic progression. <i>Cancer Research</i> , 2006 , 66, 5537-9	10.1	8
92	Delineation, functional validation, and bioinformatic evaluation of gene expression in thyroid follicular carcinomas with the PAX8-PPARG translocation. <i>Clinical Cancer Research</i> , 2006 , 12, 1983-93	12.9	108
91	Histone deacetylase inhibitors deplete enhancer of zeste 2 and associated polycomb repressive complex 2 proteins in human acute leukemia cells. <i>Molecular Cancer Therapeutics</i> , 2006 , 5, 3096-104	6.1	98
90	Ataxia telangiectasia mutated down-regulates phospho-extracellular signal-regulated kinase 1/2 via activation of MKP-1 in response to radiation. <i>Cancer Research</i> , 2006 , 66, 11554-9	10.1	24
89	Identification of EZH2 as a molecular marker for a precancerous state in morphologically normal breast tissues. <i>Cancer Research</i> , 2006 , 66, 4095-9	10.1	103
88	Activation of mitogen-activated protein kinase in estrogen receptor alpha-positive breast cancer cells in vitro induces an in vivo molecular phenotype of estrogen receptor alpha-negative human breast tumors. <i>Cancer Research</i> , 2006 , 66, 3903-11	10.1	190
87	Differential phosphoprotein mapping in cancer cells using protein microarrays produced from 2-D liquid fractionation. <i>Analytical Chemistry</i> , 2006 , 78, 702-10	7.8	28
86	Defining aggressive prostate cancer using a 12-gene model. <i>Neoplasia</i> , 2006 , 8, 59-68	6.4	73
85	ADAM15 disintegrin is associated with aggressive prostate and breast cancer disease. <i>Neoplasia</i> , 2006 , 8, 319-29	6.4	73
84	Noninvasive detection of TMPRSS2:ERG fusion transcripts in the urine of men with prostate cancer. <i>Neoplasia</i> , 2006 , 8, 885-8	6.4	174
83	Whole transcriptome amplification for gene expression profiling and development of molecular archives. <i>Neoplasia</i> , 2006 , 8, 153-62	6.4	38
82	TMPRSS2:ETV4 gene fusions define a third molecular subtype of prostate cancer. <i>Cancer Research</i> , 2006 , 66, 3396-400	10.1	387

81	Cancer immunomics: using autoantibody signatures in the early detection of prostate cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2006 , 24, 237-42	2.8	43
80	Molecular markers of prostate cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2006 , 24, 538-51	2.8	58
79	Metastasis suppressor gene Raf kinase inhibitor protein (RKIP) is a novel prognostic marker in prostate cancer. <i>Prostate</i> , 2006 , 66, 248-56	4.2	167
78	Bioinformatics approach leads to the discovery of the TMPRSS2:ETS gene fusion in prostate cancer. <i>Laboratory Investigation</i> , 2006 , 86, 1099-102	5.9	28
77	Purification of an MLL Partner Associated Complex (MPAC) Suggests a Common Role for MLL Fusion Partners in Transcriptional Elongation.. <i>Blood</i> , 2006 , 108, 770-770	2.2	
76	Development of an internally controlled antibody microarray. <i>Molecular and Cellular Proteomics</i> , 2005 , 4, 1664-72	7.6	37
75	The Polycomb group protein EZH2 impairs DNA repair in breast epithelial cells. <i>Neoplasia</i> , 2005 , 7, 1011-1014	6.4	79
74	Autoantibody signatures in prostate cancer. <i>New England Journal of Medicine</i> , 2005 , 353, 1224-35	59.2	521
73	Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. <i>Science</i> , 2005 , 310, 644-8	33.3	3022
72	Probabilistic model of the human protein-protein interaction network. <i>Nature Biotechnology</i> , 2005 , 23, 951-9	44.5	338
71	Mining for regulatory programs in the cancer transcriptome. <i>Nature Genetics</i> , 2005 , 37, 579-83	36.3	150
70	Integrative genomic and proteomic analysis of prostate cancer reveals signatures of metastatic progression. <i>Cancer Cell</i> , 2005 , 8, 393-406	24.3	625
69	Covariate adjustment in the analysis of microarray data from clinical studies. <i>Functional and Integrative Genomics</i> , 2005 , 5, 18-27	3.8	9
68	Classification and selection of biomarkers in genomic data using LASSO. <i>Journal of Biomedicine and Biotechnology</i> , 2005 , 2005, 147-54		79
67	Serum antibodies to huntingtin interacting protein-1: a new blood test for prostate cancer. <i>Cancer Research</i> , 2005 , 65, 4126-33	10.1	47
66	Identification of GATA3 as a breast cancer prognostic marker by global gene expression meta-analysis. <i>Cancer Research</i> , 2005 , 65, 11259-64	10.1	221
65	The unfolded protein response modulates toxicity of the expanded glutamine androgen receptor. <i>Journal of Biological Chemistry</i> , 2005 , 280, 21264-71	5.4	46
64	Mechanisms of enhanced radiation response following epidermal growth factor receptor signaling inhibition by erlotinib (Tarceva). <i>Cancer Research</i> , 2005 , 65, 3328-35	10.1	313

63	A germline DNA polymorphism enhances alternative splicing of the KLF6 tumor suppressor gene and is associated with increased prostate cancer risk. <i>Cancer Research</i> , 2005 , 65, 1213-22	10.1	182
62	Large-scale meta-analysis of cancer microarray data identifies common transcriptional profiles of neoplastic transformation and progression. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2004 , 101, 9309-14	11.5	790
61	Radiosensitization by pan ErbB inhibitor CI-1033 in vitro and in vivo. <i>Clinical Cancer Research</i> , 2004 , 10, 691-700	12.9	78
60	The role of metastasis-associated protein 1 in prostate cancer progression. <i>Cancer Research</i> , 2004 , 64, 825-9	10.1	116
59	Overexpression, amplification, and androgen regulation of TPD52 in prostate cancer. <i>Cancer Research</i> , 2004 , 64, 3814-22	10.1	136
58	JAGGED1 expression is associated with prostate cancer metastasis and recurrence. <i>Cancer Research</i> , 2004 , 64, 6854-7	10.1	280
57	Androgen-independent prostate cancer is a heterogeneous group of diseases: lessons from a rapid autopsy program. <i>Cancer Research</i> , 2004 , 64, 9209-16	10.1	712
56	Integration of high-resolution array comparative genomic hybridization analysis of chromosome 16q with expression array data refines common regions of loss at 16q23-qter and identifies underlying candidate tumor suppressor genes in prostate cancer. <i>Oncogene</i> , 2004 , 23, 3487-94	9.2	73
55	RhoC induces differential expression of genes involved in invasion and metastasis in MCF10A breast cells. <i>Breast Cancer Research and Treatment</i> , 2004 , 84, 3-12	4.4	65
54	Bioinformatics strategies for translating genome-wide expression analyses into clinically useful cancer markers. <i>Annals of the New York Academy of Sciences</i> , 2004 , 1020, 32-40	6.5	49
53	Humoral immune response to alpha-methylacyl-CoA racemase and prostate cancer. <i>Journal of the National Cancer Institute</i> , 2004 , 96, 834-43	9.7	113
52	Whole genome scanning identifies genotypes associated with recurrence and metastasis in prostate tumors. <i>Human Molecular Genetics</i> , 2004 , 13, 1303-13	5.6	158
51	ONCOMINE: a cancer microarray database and integrated data-mining platform. <i>Neoplasia</i> , 2004 , 6, 1-6	6.4	2548
50	Expression of the platelet-derived growth factor receptor in prostate cancer and treatment implications with tyrosine kinase inhibitors. <i>Neoplasia</i> , 2004 , 6, 503-12	6.4	39
49	Elevated alpha-methylacyl-CoA racemase enzymatic activity in prostate cancer. <i>American Journal of Pathology</i> , 2004 , 164, 787-93	5.8	62
48	Quantitative determination of expression of the prostate cancer protein alpha-methylacyl-CoA racemase using automated quantitative analysis (AQUA): a novel paradigm for automated and continuous biomarker measurements. <i>American Journal of Pathology</i> , 2004 , 164, 831-40	5.8	135
47	C5a-induced gene expression in human umbilical vein endothelial cells. <i>American Journal of Pathology</i> , 2004 , 164, 849-59	5.8	134
46	FIZZ1 stimulation of myofibroblast differentiation. <i>American Journal of Pathology</i> , 2004 , 164, 1315-26	5.8	161

45	Multiplex biomarker approach for determining risk of prostate-specific antigen-defined recurrence of prostate cancer. <i>Journal of the National Cancer Institute</i> , 2003 , 95, 661-8	9.7	220
44	Statistical issues and methods for meta-analysis of microarray data: a case study in prostate cancer. <i>Functional and Integrative Genomics</i> , 2003 , 3, 180-8	3.8	63
43	Expression of CXCR4 and CXCL12 (SDF-1) in human prostate cancers (PCa) in vivo. <i>Journal of Cellular Biochemistry</i> , 2003 , 89, 462-73	4.7	370
42	Prostate cancer biomarkers: a current perspective. <i>Expert Review of Molecular Diagnostics</i> , 2003 , 3, 459-70	3.8	13
41	Dysregulation of the annexin family protein family is associated with prostate cancer progression. <i>American Journal of Pathology</i> , 2003 , 162, 255-61	5.8	149
40	Development of human protein reference database as an initial platform for approaching systems biology in humans. <i>Genome Research</i> , 2003 , 13, 2363-71	9.7	823
39	The role of calpain in the proteolytic cleavage of E-cadherin in prostate and mammary epithelial cells. <i>Journal of Biological Chemistry</i> , 2003 , 278, 1372-9	5.4	134
38	EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2003 , 100, 11606-11	11.5	1295
37	Diagnostic usefulness of monoclonal antibody P504S in the workup of atypical prostatic glandular proliferations. <i>American Journal of Clinical Pathology</i> , 2003 , 120, 737-45	1.9	5
36	Transcriptome analysis of HER2 reveals a molecular connection to fatty acid synthesis. <i>Cancer Research</i> , 2003 , 63, 132-9	10.1	136
35	The role of an 80 kDa fragment of E-cadherin in the metastatic progression of prostate cancer. <i>Clinical Cancer Research</i> , 2003 , 9, 6447-52	12.9	64
34	The polycomb group protein EZH2 is involved in progression of prostate cancer. <i>Nature</i> , 2002 , 419, 624-9	30.4	2085
33	Molecular cross-talk between the TRAIL and interferon signaling pathways. <i>Journal of Biological Chemistry</i> , 2002 , 277, 575-85	5.4	75
32	alpha-Methylacyl coenzyme A racemase as a tissue biomarker for prostate cancer. <i>JAMA - Journal of the American Medical Association</i> , 2002 , 287, 1662-70	27.4	489
31	Gene-expression profiles in hereditary breast cancer. <i>Advances in Anatomic Pathology</i> , 2002 , 9, 1-6	5.1	4
30	Alpha-Methylacyl-CoA racemase: a novel tumor marker over-expressed in several human cancers and their precursor lesions. <i>American Journal of Surgical Pathology</i> , 2002 , 26, 926-31	6.7	236
29	alpha-Methylacyl-CoA racemase: expression levels of this novel cancer biomarker depend on tumor differentiation. <i>American Journal of Pathology</i> , 2002 , 161, 841-8	5.8	105
28	Changes in differential gene expression because of warm ischemia time of radical prostatectomy specimens. <i>American Journal of Pathology</i> , 2002 , 161, 1743-8	5.8	124

27	DNA microarrays: implications for clinical medicine. <i>Journal of Investigative Surgery</i> , 2002 , 15, 275-9	1.2	11
26	A functional thrombin receptor (PAR1) is expressed on bone-derived prostate cancer cell lines. <i>Urology</i> , 2002 , 60, 760-5	1.6	83
25	Using Protein Microarrays to Study Cancer. <i>BioTechniques</i> , 2002 , 33, S46-S53	2.5	17
24	High and selective expression of yeast cytosine deaminase under a carcinoembryonic antigen promoter-enhancer. <i>Cancer Research</i> , 2002 , 62, 2337-42	10.1	26
23	Meta-analysis of microarrays: interstudy validation of gene expression profiles reveals pathway dysregulation in prostate cancer. <i>Cancer Research</i> , 2002 , 62, 4427-33	10.1	460
22	Protein microarrays: a powerful tool to study cancer. <i>Current Opinion in Molecular Therapeutics</i> , 2002 , 4, 587-93		1
21	Delineation of prognostic biomarkers in prostate cancer. <i>Nature</i> , 2001 , 412, 822-6	50.4	1402
20	Molecular signatures of sepsis: multiorgan gene expression profiles of systemic inflammation. <i>American Journal of Pathology</i> , 2001 , 159, 1199-209	5.8	173
19	The apoptosome: heart and soul of the cell death machine. <i>Neoplasia</i> , 1999 , 1, 5-15	6.4	157
18	A caspase-resistant form of Bcl-X(L), but not wild type Bcl-X(L), promotes clonogenic survival after ionizing radiation. <i>Neoplasia</i> , 1999 , 1, 63-70	6.4	8
17	A role for FADD in T cell activation and development. <i>Immunity</i> , 1998 , 8, 439-49	32.3	218
16	The death inhibitory molecules CED-9 and CED-4L use a common mechanism to inhibit the CED-3 death protease. <i>Journal of Biological Chemistry</i> , 1998 , 273, 17708-12	5.4	28
15	Ultraviolet radiation-induced apoptosis is mediated by activation of CD-95 (Fas/APO-1). <i>Journal of Biological Chemistry</i> , 1997 , 272, 25783-6	5.4	246
14	The receptor for the cytotoxic ligand TRAIL. <i>Science</i> , 1997 , 276, 111-3	33.3	1514
13	Portrait of an executioner: the molecular mechanism of FAS/APO-1-induced apoptosis. <i>Seminars in Immunology</i> , 1997 , 9, 69-76	10.7	87
12	Keystone 1997: return of the worm. Temarron, Colorado, February 18-23, 1997. <i>Cell Death and Differentiation</i> , 1997 , 4, 519-21	12.7	
11	The inhibition of pro-apoptotic ICE-like proteases enhances HIV replication. <i>Nature Medicine</i> , 1997 , 3, 333-7	50.5	76
10	Role of CED-4 in the activation of CED-3. <i>Nature</i> , 1997 , 388, 728-9	50.4	174

9	ICE-LAP3, a novel mammalian homologue of the <i>Caenorhabditis elegans</i> cell death protein Ced-3 is activated during Fas- and tumor necrosis factor-induced apoptosis. <i>Journal of Biological Chemistry</i> , 1996 , 271, 1621-5	5-4	235
8	FLICE, a novel FADD-homologous ICE/CED-3-like protease, is recruited to the CD95 (Fas/APO-1) death-inducing signaling complex. <i>Cell</i> , 1996 , 85, 817-27	56.2	2715
7	Signal transduction by DR3, a death domain-containing receptor related to TNFR-1 and CD95. <i>Science</i> , 1996 , 274, 990-2	33.3	577
6	ICE-LAP6, a novel member of the ICE/Ced-3 gene family, is activated by the cytotoxic T cell protease granzyme B. <i>Journal of Biological Chemistry</i> , 1996 , 271, 16720-4	5-4	225
5	The cell-death machine. <i>Current Biology</i> , 1996 , 6, 555-62	6.3	334
4	Cytotoxic T-cell-derived granzyme B activates the apoptotic protease ICE-LAP3. <i>Current Biology</i> , 1996 , 6, 897-9	6.3	93
3	Molecular ordering of the cell death pathway. Bcl-2 and Bcl-xL function upstream of the CED-3-like apoptotic proteases. <i>Journal of Biological Chemistry</i> , 1996 , 271, 4573-6	5-4	471
2	FADD/MORT1 is a common mediator of CD95 (Fas/APO-1) and tumor necrosis factor receptor-induced apoptosis. <i>Journal of Biological Chemistry</i> , 1996 , 271, 4961-5	5-4	598
1	FADD, a novel death domain-containing protein, interacts with the death domain of Fas and initiates apoptosis. <i>Cell</i> , 1995 , 81, 505-12	56.2	2110